Retatrutide Side Effects: What Phase 2 Trial Data Shows

The Phase 2 clinical trial for retatrutide identified gastrointestinal adverse events as the most frequently reported side effects, consistent with the broader GLP-1 medication class. The most common were:

Nausea: The most frequently reported side effect across all dose groups. Typically onset during the early weeks of treatment and during dose escalation periods.

Diarrhea: Reported across all dose groups with increasing frequency at higher doses.

Vomiting: Less common than nausea but still reported at clinically relevant rates, particularly in the higher dose groups.

Decreased appetite: Often reported as a side effect but also a primary mechanism of action -- reduced appetite is how GLP-1 medications produce weight loss.

Constipation: Reported in some participants, reflecting the medication's effect on gastric motility.

Side effects in the retatrutide trial followed a clear dose-dependent pattern. Participants in the 1 mg and 2 mg groups reported lower rates of GI symptoms compared to those in the 8 mg and 12 mg groups. This is the same pattern observed with semaglutide and tirzepatide -- higher doses produce more pronounced effects on the GI tract.

Most side effects were classified as mild to moderate in severity. Mild means the symptoms were noticeable but did not interfere with daily activities. Moderate means symptoms caused some interference but did not require discontinuation. Severe GI events leading to treatment discontinuation were uncommon.

The dose escalation protocol used in the trial -- starting at a low dose and gradually increasing over several weeks -- was specifically designed to reduce the incidence and severity of these effects. Patients who follow a gradual titration schedule generally tolerate GLP-1 medications better than those who start at higher doses.

The side effect profile of retatrutide in Phase 2 was qualitatively similar to what has been observed with semaglutide and tirzepatide. All three medications cause the same core GI symptoms -- nausea, diarrhea, vomiting, and decreased appetite -- because they all activate GLP-1 receptors, which affect gastric motility and appetite signaling.

The addition of glucagon receptor agonism in retatrutide did not appear to introduce fundamentally new or unexpected side effects in the Phase 2 data. However, Phase 2 trials are relatively small (approximately 340 participants) and may not capture rare adverse events that larger Phase 3 trials will detect.

Rates of GI side effects in the retatrutide trial were generally in line with or slightly higher than rates seen in tirzepatide trials, which may partly reflect the triple-receptor mechanism or the specific dose escalation schedule used.

Phase 3 trials, which involve thousands of participants over longer durations, will provide a much more comprehensive picture of retatrutide's safety profile. Specifically, these trials will help determine:

Long-term safety beyond 48 weeks, including cardiovascular outcomes, liver function, and kidney function.

Rare adverse events that may not have appeared in the smaller Phase 2 population.

Safety in specific subpopulations such as patients with type 2 diabetes, cardiovascular disease, or liver disease.

The impact of different dose escalation schedules on tolerability.

Until Phase 3 data is available, the safety profile of retatrutide should be considered preliminary. The Phase 2 results are encouraging -- no novel safety signals emerged -- but the full picture requires larger and longer studies.